Nov
12
2019
On demand
Meeting the scalability challenge of downstream viral vector purification
Sponsor
In the expanding field of gene and cell therapy, continuous flow ultracentrifugation is slowly revealing its ability to overcome downstream bottlenecks. Unlike the more well-known tube rotor designs, continuous flow zonal UCF offers a unique ability to dynamically use revolving zones at high speeds to provide a scalable and cost-effective process for the purification and concentration of viral vectors.
- Understand the capabilities and benefits of continuous flow ultracentrifugation to purify and concentrate viral vectors (including AAV) in a predictable manner.
- Assess the scalability and cost-effectiveness of solutions to downstream bottlenecks and gene therapy process development.
- Discover what makes linear scalability possible with continuous flow ultracentrifugation.
- Learn how to improve your product recovery and process time.
You might also like
Focus on allogeneic CAR-Ts manufacturing challenges and solutions
M Langtry, A Sargent, B Baghbaderani
15 March 2023
Simplifying GMP CAR-T and CAR NK cell therapy manufacturing processes
M Luevano, X Wang, S Fricke et al.
9 June 2022
Large-scale LVV production: from industry-leading process development to high quality GMP vector
25 February 2021
Exploring the capabilities of a versatile, novel, automated closed system for cell and gene therapy manufacturing
16 February 2021
Fitting product to process: raw materials customization for cell therapy manufacturing success
J Tomtishen III, L Clarke, PhD, L Belcastro et al.
11 February 2021